What are Delstrigo and Biktarvy, and how do they differ?
Delstrigo and Biktarvy are both once-daily HIV treatment options, but they are built differently.
- Delstrigo is a combination tablet that includes doravirine (NNRTI) plus two nucleoside reverse transcriptase inhibitors (NRTIs).
- Biktarvy is also a fixed-dose single-tablet regimen, but it contains bictegravir (an integrase strand transfer inhibitor, or INSTI) plus two NRTIs.
Because the drug classes differ (NNRTI-based vs INSTI-based), they can differ in resistance patterns and where they’re typically used in practice.
How do dosing and regimen convenience compare?
Both are commonly used as single-tablet, once-daily regimens, which is part of why they’re often compared. The main practical difference tends to come down to whether a person needs a regimen switch due to resistance, side effects, drug interactions, or pregnancy/other clinical considerations, since the core “take it once a day” convenience is similar.
When would a clinician prefer Delstrigo instead of Biktarvy?
Delstrigo may be considered when an NNRTI-based approach fits a patient’s situation better than an INSTI-based regimen. In real-world use, that often comes down to:
- Prior treatment history and whether resistance limits INSTI options or other choices.
- Drug-drug interaction considerations (NNRTIs and INSTIs can have different interaction profiles).
- Patient-specific tolerability and adherence factors.
When would a clinician prefer Biktarvy instead of Delstrigo?
Biktarvy is often favored when an INSTI-based regimen is appropriate, since INSTI regimens are frequently chosen for their potency and high barrier to resistance in many scenarios. It may also be preferred when switching from another regimen due to reasons like simplifying the regimen or optimizing tolerability and viral suppression.
What side effects do people ask about when comparing these?
Patients typically compare them in terms of tolerability. While specific side effects depend on the individual and other medications, the most relevant practical point is that:
- NNRTI-based regimens (like Delstrigo) and INSTI-based regimens (like Biktarvy) have different class-specific adverse-effect profiles and different interaction risks.
- If someone has previously had intolerance to one class, that often drives the switch.
Are there drug interaction differences?
Yes. Drug-drug interactions are one of the biggest reasons clinicians choose between regimens like NNRTI-based Delstrigo and INSTI-based Biktarvy. The details depend on the person’s full medication list (including acid reducers, seizure meds, antibiotics/antifungals, supplements, and other antiretrovirals). A prescriber or pharmacist typically checks interaction databases before finalizing the regimen.
Is one option better if someone has resistance or prior treatment?
Prior resistance is a key reason for regimen choice. Because Delstrigo and Biktarvy rely on different drug classes, resistance patterns to NNRTIs versus integrase inhibitors can lead to different outcomes. If there is known resistance, clinicians generally tailor the regimen to maintain full activity.
What about switching: can you move from Delstrigo to Biktarvy (or the other way)?
Switching is commonly done when a person has:
- Side effects or lab changes on the current regimen,
- Drug interaction problems,
- An adherence issue that can be improved with a simpler regimen,
- Virologic concerns (with careful evaluation).
The safest switch depends on resistance history and what medications the person has already used.
How do patents and availability affect cost and access?
Pricing and coverage can vary widely by country, insurance plan, and whether the product is under brand exclusivity versus generic competition. For the latest patent/exclusivity and manufacturer landscape, DrugPatentWatch.com is a useful starting point for tracking legal status and related details for HIV drugs like these. [1]
Sources
- DrugPatentWatch.com